首页> 外文期刊>Drug Design, Development and Therapy >Human mesenchymal stem cells as delivery of?osteoprotegerin gene: homing and therapeutic effect for osteosarcoma
【24h】

Human mesenchymal stem cells as delivery of?osteoprotegerin gene: homing and therapeutic effect for osteosarcoma

机译:人间充质干细胞作为骨保护素基因的传递:对骨肉瘤的归巢和治疗作用

获取原文
           

摘要

Abstract: Biological treatments have been studied extensively and previous studies have proved that osteoprotegerin (OPG) can inhibit the development and progress of human osteosarcoma. However, the utility of biologic agents for cancer therapy has a short half-life, which can hardly deliver to and function in tumor sites efficiently. Mesenchymal stem cells (MSCs) have the potential to migrate to tumor sites. In this study, MSCs transfected with adenoviruses carrying the OPG gene (MSCs-OPG) were used via the tail vein to treat athymic nude mice (nuu) bearing osteosarcoma. In vivo and ex vivo images were used to validate the MSCs homing to tumors. The therapeutic effect for osteosarcoma was evaluated by observations on growth of tumors and bone destruction. The results showed that infected MSCs-OPG labeled with red fluorescent protein (RFP) can migrate to tumor sites and express OPG protein. The treatment by MSCs-OPG reduced the tumor growth and inhibited bone destruction in vivo. All these indicated that MSCs can deliver OPG to tumor sites, which could be a new direction of biological treatment for human osteosarcoma.
机译:摘要:生物治疗已被广泛研究,并且先前的研究证明骨保护素(OPG)可以抑制人类骨肉瘤的发展和进展。但是,用于癌症治疗的生物制剂的半衰期短,几乎不能有效地递送至肿瘤部位并在肿瘤部位起作用。间充质干细胞(MSC)具有迁移到肿瘤部位的潜力。在这项研究中,转染带有OPG基因的腺病毒(MSCs-OPG)的MSCs通过尾静脉用于治疗携带骨肉瘤的无胸腺裸鼠(nu / nu)。体内和离体图像用于验证MSC归巢于肿瘤。通过观察肿瘤的生长和骨破坏来评估对骨肉瘤的治疗效果。结果表明,感染的MSCs-OPG标记有红色荧光蛋白(RFP)可以迁移到肿瘤部位并表达OPG蛋白。 MSCs-OPG的治疗降低了肿瘤的生长,并在体内抑制了骨的破坏。所有这些表明,MSC可以将OPG递送至肿瘤部位,这可能是人骨肉瘤生物学治疗的新方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号